Clinical effect of torsemide in a horse with congestive heart failure and atrial fibrillation.

The study describes the impact of the drug torsemide on a horse suffering from congestive heart failure and atrial fibrillation. It comments on the drug’s effectiveness, the horse’s response to the treatment, and its potential as an alternate drug to be used in similar scenarios.

Methodology

• The researchers administered a high dose of torsemide orally to a horse already diagnosed with CHF (Congestive Heart Failure) and atrial fibrillation.
• The medication was given at a dosage of 6mg/kg every 12 hours for the first three days, followed by 12mg/kg every 12 hours for the subsequent four days
• Blood samples were taken hourly after each dosage to measure plasma torsemide concentrations and observe its presence and effect in the horse’s system
• Daily evaluations, including physical examinations, electrocardiography, and serum biochemistry, were conducted to determine the after-effects of torsemide.

Findings

• The horse responded well to torsemide administration, indicating that the drug was well-tolerated.
• A significant reduction in ventral oedema (a type of swelling) and venous congestion was observed on the seventh day of the treatment.
• Plasma torsemide concentrations saw a steep increase on day five, recording a peak concentration of 15.41 µg/mL.
• The study also observed an increase in renal markers, denoting more active or efficient kidney function.
• Electrolyte measurements showed mild decreases in sodium (hyponatremia) and chlorine (hypochloremia) levels, and a moderate reduction in potassium (hypokalaemia).
• There were no observable changes in the horse’s electrocardiogram, suggesting that the drug had no adverse effects on the heart’s electrical activity.
• Despite the initial improvements, the horse was euthanised after the seventh day, given the poor prognosis and advancement stage of the disease.

Conclusion and Future Implications

• This case study shows that torsemide was absorbed and well-tolerated when orally administered to a horse, hinting at its potential as a possible alternative to furosemide in managing patients suffering from equine CHF.
• However, the researchers caution that the high dosage of torsemide used in this case should only be considered in cases where there is no clinical response to smaller doses and should be monitored closely for any changes in electrolyte levels and renal function parameters.
• The study concludes that further investigation of the clinical efficacy and safety of torsemide in treating horses with CHF, incorporating a larger cohort and extended administration period, is recommended.